Business
Sevion Therapeutics Presents Results of SNS01-T Phase 1b/2a Dose Escalation Study at ASH Annual Meeting
Sevion Therapeutics Presents Results of SNS01-T Phase 1b/2a Dose Escalation Study at ASH Annual Meeting.
About this update from Eloxx Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n Sevion Therapeutics (OTCQB:SVON), a biopharmaceutical company which \n discovers, develops and acquires next-generation biologics for the \n treatment of cancer and immunological diseases, today announced the \n presentation of results from the Company’s Phase 1b/2a clinical trial of \n SNS01-T for the treatment of multiple myeloma and lymphoma. The results \n were presented in a poster session titled “Lymphoma: Therapy with \n Biologic Agents, excluding Pre-Clinical Models: Poster III” at the 56th \n American Society of Hematology (ASH) Annual Meeting and Exposition in \n San Francisco.\n \n \n The study, “Mature Results of a Phase 1-2 Open-Label, Dose-Escalation \n Study of Intravenous SNS01-T in Patients with Relapsed or Refractory B \n Cell Malignancies,” was an open-label, multiple-dose, dose-escalation \n study to evaluate the safety and tolerability of SNS01-T when \n administered by intravenous infusion to patients with relapsed or \n refractory multiple myeloma, mantle cell (MCL) or diffuse large B-cell \n lymphoma (DLBCL). The primary objective of the study was to evaluate \n safety and tolerability. Secondary objectives included pharmacokinetics, \n tumor response markers, and time to relapse or progression.\n \n \n Of 22 patients treated, 14 patients were evaluable for dose limiting \n toxicity. Of four dose cohorts tested, the maximum tolerated dose was \n determined to be the third dose group, at 0.2 mg/Kg. The most frequent \n adverse events were fatigue, infusion reaction, nausea, thrombocytopenia \n and chills, with no treatment related deaths. Two dose limited \n toxicities were observed in the fourth dose group (0.375 mg/Kg), \n including Grade 4 infusion reaction and Grade 4 neutropenia. Potential \n treatment effects were observed in cohorts 3 and 4, with a 44% reduction \n in sum of product of tumor diameter in 1 of 3 lymphoma patients lasting \n 30 weeks; a 15% and 33% reduction in serum and urine monoclonal proteins \n (SPEP and UPEP), and a 19% free light chain (FLC) ratio decrease lasting \n 10 weeks in one of two patients with multiple myeloma enrolled in cohort \n 3; and a 21-30% UPEP reduction and 0-42% FLC ratio decrease lasting 3 to \n 6 weeks in 2 of 6 evaluable patients with multiple myeloma in cohort 4.\n \n \n “Modulation of Factor 5A has the potential ...